Novartis Female Sales Reps Win Verdict Against Novartis Pharmaceuticals In Gender Bias & Sex Discrimination Class Action Lawsuit
The five week trial in a class action lawsuit against drug maker Novartis Pharmaceuticals Corporation pending in the United States District Court for the Southern District of New York (styled Amy Velez v. Novartis Pharmaceuticals Corporation, Case No. 04-cv-9194) alleging gender discrimination in pay, promotional opportunities and pregnancy-related matters in violation of Title VII of the Civil Rights Act has reached a verdict in favor of the Novartis female employee plaintiffs, according to a class action news report.
In addition to the Novartis verdict, the jury in the Novartis gender discrimination class action lawsuit awarded 12 testifying witnesses approximately $3.36 million in compensatory damages for specific instances of discrimination that they testified to.
Judge Colleen McMahon reportedly will determine a separate amount of class damages, including back-pay damages for lost earnings. The Novartis sex discrimination class includes approximately 5,600 female sales representative employees that worked for Novartis between 2002 and 2007.
Compensatory damages, such as money for pain and suffering, will reportedly be decided, in separate proceedings, for each member of the class that opts-in to the Novartis gender discrimination class action lawsuit. Plaintiffs are also reportedly seeking an order requiring Novartis to make changes to its policies and procedures.
For more information on the Novartis Pharmaceuticals gender discrimination class action lawsuit allegations, read the Novartis Class Action Complaint.
Novartis Gender Discrimination Class Action Update:
A New York jury has reportedly awarded an additional $250 million in punitive damages for gender discrimination in the class action suit against Novartis.
If You Have Thoughts On The Novartis Pharmaceuticals Gender Bias & Sex Discrimination Class Action Lawsuit, Share Your Class Action Comments Below.